HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry

被引:146
作者
Pugach, Pavel [1 ]
Marozsan, Andre J. [1 ]
Ketas, Thomas J. [1 ]
Landes, Elissa L. [1 ]
Moore, John P. [1 ]
Kuhmann, Shawn E. [1 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA
关键词
HIV-1; CCR5; entry inhibition; resistance; escape mutants;
D O I
10.1016/j.virol.2006.11.004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human immunodeficiency virus type 1 (HIV-1) infection can be inhibited by small molecules that target the CCR5 coreceptor. Here, we describe some properties of clonal viruses resistant to one such inhibitor, SCH-D, using both chimeric, infectious molecular clones and Envpseudotypes. Studies using combinations of CCR5 ligands, including small molecule inhibitors, monoclonal antibodies (MAbs) and chemokine derivatives such as PSC-RANTES, show that the fully SCH-D-resistant viruses enter target cells by using the SCH-D-bound form of CCR5. However, the way resistance to SCH-D and other small molecule CCR5 inhibitors is manifested depends on the target cell and the nature of the assay (single- vs. multi-cycle). In multi-cycle assays using primary lymphocytes, SCH-D does not inhibit resistant molecular clones, and it can even enhance their infectivity modestly. In contrast, the same viruses (as Env-pseudotypes) are significantly inhibited by SCH-D in single-cycle entry assays using U87-CD4/CCR5 cells, resistance being manifested by incomplete inhibition at high SCH-D concentrations. When a single-cycle, Env-pseudotype entry assay was performed using either U87-CD4/CCR5 cells or PBMC under comparable conditions, entry was inhibited by up to 88% in the former cells but by only 28% in the PBMC. Hence, there are both cell- and assay-dependent influences on how resistance is manifested. We also take this opportunity to correct our previous report that SCH-D-resistant isolates are also substantially cross-resistant to PSC-RANTES [Marozsan, A.J., Kuhmann, S.E., Morgan, T., Herrera, C., Rivera-Troche, E., Xu, S., Baroudy, B.M., Strizki, J., Moore, J.P., 2005. Generation and properties of a human immunodeficiency virus type I isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 338 (1), 182-199]. A substantial element of this resistance was attributable to the unappreciated carry-over of SCH-D from the selection cultures into analytical assays. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:212 / 228
页数:17
相关论文
共 41 条
  • [21] Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20)
    Lu, J
    Sista, P
    Giguel, F
    Greenberg, M
    Kuritzkes, DR
    [J]. JOURNAL OF VIROLOGY, 2004, 78 (09) : 4628 - 4637
  • [22] Generation and properties of a human immunodeficiency virus type I isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D)
    Marozsan, AJ
    Kuhmann, SE
    Morgan, T
    Herrera, C
    Rivera-Troche, E
    Xu, S
    Baroudy, BM
    Strizki, J
    Moore, JP
    [J]. VIROLOGY, 2005, 338 (01) : 182 - 199
  • [23] Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates
    Marozsan, AJ
    Arts, EJ
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2003, 111 (02) : 111 - 120
  • [24] Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1
    Murga, Jose D.
    Franti, Michael
    Pevear, Daniel C.
    Maddon, Paul J.
    Olson, William C.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) : 3289 - 3296
  • [25] Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5
    Olson, WC
    Rabut, GEE
    Nagashima, KA
    Tran, DNH
    Anselma, DJ
    Monard, SP
    Segal, JP
    Thompson, DAD
    Kajumo, F
    Guo, Y
    Moore, JP
    Maddon, PJ
    Dragic, T
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (05) : 4145 - 4155
  • [26] Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposures
    Paxton, WA
    Martin, SR
    Tse, D
    OBrien, TR
    Skurnick, J
    VanDevanter, NL
    Padian, N
    Braun, JF
    Kotler, DP
    Wolinsky, SM
    Koup, RA
    [J]. NATURE MEDICINE, 1996, 2 (04) : 412 - 417
  • [27] Perspective: Research highlights at the Aaron Diamond AIDS Research Center - The beta-chemokines, HIV type 1 second receptors, and exposed uninfected persons
    Paxton, WA
    Dragic, T
    Koup, RA
    Moore, JP
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (13) : 1203 - 1207
  • [28] Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1
    Platt, EJ
    Wehrly, K
    Kuhmann, SE
    Chesebro, B
    Kabat, D
    [J]. JOURNAL OF VIROLOGY, 1998, 72 (04) : 2855 - 2864
  • [29] The prolonged culture of human immunodeficiency virus type I in primary lymphocytes increases its sensitivity to neutralization by soluble CD4
    Pugach, P
    Kuhmann, SE
    Taylor, J
    Marozsan, AJ
    Snyder, A
    Ketas, T
    Wolinsky, SM
    Korber, BT
    Moore, JP
    [J]. VIROLOGY, 2004, 321 (01) : 8 - 22
  • [30] An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry
    Safarian, Diana
    Carnec, Xavier
    Tsamis, Fotini
    Kajumo, Francis
    Dragic, Tatjana
    [J]. VIROLOGY, 2006, 352 (02) : 477 - 484